We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01199094
First Posted: September 10, 2010
Last Update Posted: September 10, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Odense University Hospital
September 9, 2010
September 10, 2010
September 10, 2010
January 2009
April 2010   (Final data collection date for primary outcome measure)
Bone microarchitecture as assessed by high resolution quantitative computed tomography (HR-pQCT) [ Time Frame: 12 weeks ]
HR-pQCT is used to evaluate bone microarchitecture, i.e. bone trabeculae, cortical thickness and trabecular number. Aim is to test if the microarchitecture of these patients are different that observed in normal controls
Same as current
No Changes Posted
  • Changes in bone turnover markers [ Time Frame: 12 weeks ]
    Markers of bone resorption and formation are investigated.
  • Bone mineral density [ Time Frame: 12 weeks ]
    DXA is used to evaluate bone mineral density at total hip, spine, whole body and forearm.
Same as current
Not Provided
Not Provided
 
Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5
Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5
The aim of the study is to describe patients with a high bone mass phenotype due to a mutation in the low density lipoprotein l receptor 5 gene (LRP5) and compare them with age and sex matched controls. Moreover, bone density and microarchitecture as well as markers of bone metabolism are evaluated

Cases and controls are closely matched on age and sex and evaluated cross-sectionally.

Dual x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HR-pQCT) are used in order to evaluate bone density as well as microarchitecture. Bone turnover markers and body composition are also measured.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
Serum, plasma, DNA as well as fat and skin biopsies
Non-Probability Sample
Case-control study on almost 40 individuals
Osteopetrosis
Not Provided
Patients with mutation in the Lrp5 gene
Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010 Mar;25(3):673-5. doi: 10.1002/jbmr.44. Erratum in: J Bone Miner Res. 2010 Aug;25(8):1896.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
June 2010
April 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Lrp5 mutation/ADOI

Exclusion Criteria:

  • Pregnancy
Sexes Eligible for Study: All
8 Years and older   (Child, Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT01199094
LRP5-HBM
No
Not Provided
Not Provided
Kim Brixen, Professor, consultant, Odense University Hospital
Odense University Hospital
Not Provided
Principal Investigator: Kim Brixen, Professor Odense University Hospital
Odense University Hospital
August 2010